For Continuing Medical Education for Physicians (CME):
The Centers for Disease Control and Prevention is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians.
The Centers for Disease Control and Prevention designates this educational activity for a maximum of (17.5) AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Continuing Education designated for Non-Physicians:
Non-physicians will receive a certificate of participation.
For Continuing Nursing Education for Nurses (CNE):
The Centers for Disease Control and Prevention is accredited as a provider of Continuing Nursing Education by the American Nurses Credentialing Center's Commission on Accreditation.
This activity provides (17.5) contact hours.
IACET Continuing Education Units (CEU):
The CDC has been approved as an Authorized Provider by the International Association for Continuing Education and Training (IACET), 1760 Old Meadow Road, Suite 500, McLean, VA 22102. The CDC is authorized by IACET to offer (1.8) ANSI/IACET CEU's for this program.
For Continuing Education Contact Hours in Health Education (CECH):
Sponsored by the Centers for Disease Control and Prevention, a designated provider of continuing education contact hours (CECH) in health education by the National Commission for Health Education Credentialing, Inc. This program is designed for Certified Health Education Specialists (CHES) to receive up to 17.5 Category I CECH in health education. CDC provider number GA0082.
For Continuing Education for Veterinarians (AAVSB/RACE):
This program was reviewed and approved by the AAVSB RACE program for continuing education. Please contact the AAVSB Race Program at
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
should you have any comments/concerns regarding this program's validity or relevancy to the veterinary profession.
For Continuing Pharmacy Education (CPE):
The Centers for Disease Control and Prevention is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
This program is a designated event for pharmacists to receive 17.5 Contact Hours in pharmacy education. The Universal Activity Number is 0387-9999-10-024-L01-P.
Course Category: This activity has been designated as Knowledge-Based.
PROOF OF DISCLOSURE
CDC, our planners, and our presenters wish to disclose they have no financial interests or other relationships with the manufacturers of commercial products, suppliers of commercial services, or commercial supporters with the exception of:
- Dr. Elizabeth Barnett wishes to disclose receiving grant support from Sanofi Pasteur.
- Dr. Ellen Jo Baron wishes to disclose receiving a salary and stocks from Cepheid for role as an employee; honorarium from OpGen for role on Scientific Advisory Board; stocks from MicroPhage for role on Scientific Advisory Board; honorarium from Merck for role as a consultant; stocks from Key Scientific Products for role on Scientific Advisory Board; stocks from Immunoscience for role as a consultant; honorarium from BioMerieux for role as a speaker.
- Dr. John Boslego wishes to disclose receiving salary, stocks, and options from Merck & Company, Inc for role as an employee in 1995-2006.
- Dr. Rick Bright wishes to disclose receiving stock as part of a management position in 2006 from Novavax, Inc.
- Dr. W. Abdullah Brooks wishes to disclose receiving vaccine donation from Sanofi-Pasteur for vaccine trial (ongoing).
- Dr. Lin Chen wishes to disclose receiving a honorarium from AHC Media, LLC for role as Associate Editor of Travel Medicine Advisor.
- Dr. Erik Dubberke and he wishes to disclose receiving honorariums from Merck, Meridian, and Becton-Dickinson for role as a consultant; research funding from Merck, and Viropharma for clinical trials; honorariums from Sanofi-pasteur, and Pfizer for role as a speaker.
- Dr. Janet England wishes to disclose receiving research support from MedImmune Inc, Novartis, Sanofi-Pasteur, Adamas, Inc. for role as a Research Investigator.
- Loretta Fauerbach wishes to disclose receiving an honorarium from Hospira - Theradoc for role on Infection Control Advisory Board.
- Dr. Frederick Hayden wishes to disclose receiving honoraria for lectures and consulting, receiving research support from several companies, and serving as an unpaid consultant to multiple companies ( Abbott, Adamas, Alios, Biocryst, Boerhinger-Ingelheim, Crucell, GSK, Inhibikase, Kirin, Liquidia, Nexbio, Respivert, Roche, Toyama, 3V Biosciences, and Vaxinnate.
- Dr. W. Ray Kim wishes to disclose he has received honorarium as consultant from Bristol-Myers-Squibb, Gilead Science and Roche Diagnostics.
- Dr. Laura Koutsky wishes to disclose her organization (University of Washington) receives funds from Merck.
- Dr. Stuart Levy wishes to disclose that he has received salary and stocks from Paratek Pharmaceutical as CSO.
- Dr. Ian Lipkin wishes to disclose that he has received stock options as a Scientific Advisory Board member of 454 Life Sciences.
- Dr. Kim Mulholland wishes to disclose that he has received consulting fees from Merck as part of his participation in their Advisory Board.
- Dr. Albertus Osterhaus wishes to disclose that he receives a part-time salary from ViroClinics Biosciences B.V as Chief Science Officer.
- Dr. Peter Pappas wishes to disclose receiving an honorarium from Merck, Pfizer, and Astellas for role as Ad hoc advisor.
- Dr. Andrew Pavia wishes to disclose that he has received fees as consultant for Nexbio, Abbott, and Pfizer.
- Dr. Louis Rice wishes to disclose that he has received honoraria from Theradoc, Noexel, and Tetraphase as a board member. He has also received honoraria from Achillion, Pfizer, Wyeth and Merck as either a consultant or speaker.
- Dr. Mark Rosenberg wishes to disclose the Task Force receives donated Zithromax for use in the International Trachoma Initiative program from Pfizer, Inc., donated Mectizan from Merck, Inc., and donated Mebendazole from Johnson & Johnson.
- Dr. David Smith wishes to disclose receiving an honorarium from Bioniche Life Sciences for sharing results of research studies.
- Dr. Andrew Vernon wishes to disclose that he supervises a CDC branch which supports a TB Clinical Trail group which receives research support funds from multiple pharmaceutical firms. No personal benefit derived.
- Dr. Matt Zahn wishes to disclose receiving honorariums from Sanofi Pasteur and Medimmune for role as a speaker.Presentations will not include any discussion of the unlabeled use of a product or a product under investigational use with the exception of:
- Dr. John Boslego's discussion of new vaccines currently still in development (investigational use).
- Dr. Bernard Branson's discussion of investigational products for HIV diagnosis and their implications for public health practice.
- Dr. Janet Englund's discussion of influenza vaccine in children less than 6 months of age as a potential tool for the future.
- Dr. Eileen Farnon's discussion of the use of Miltefosine for treatment of Balamuthia mandrillaris and the investigational use of parental Ivermectin use for the treatment of Strongyloides hyperinfection syndrome.
- Dr. Frederick Hayden's discussion of various investigational anti-influenza agents: IV peramivir/zanamivir/oseltamivir; laninamivir; favipiravir; DAS181;arbidol;ribavirin;immune plasma, monoclonals and immunoglobulins.
- Dr. Andre Nahmias's discussion of several investigational herpes simplex vaccine and therapeutic modalities.
- Dr. Stephen Redd's discussion of several anti-influenza drugs that were administered under emergency use authorization during the 2009 H1N1 pandemic.
- Dr. David Smith's discussion of the results of vaccine clinical trials to test the efficacy of an investigational vaccine product.
- Dr. Andrew Vernon's discussion of investigational agents for the treatment of TB.
There is no commercial support for this activity.
|
Continuing Education 
